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Background: Expression of the constitutively activated mutant EGFR variant III (EGFRvIII), the most common mutation
in glioblastoma multiforme (GBMs), has been clinically correlated with tumor proliferation, invasion, and angiogenesis.
In this study, we examined the role of EGFRvIII on the tumor microenvironment, especially on angiogenesis.
Methods: To study the role of EGFRvIII in tumor angiogenesis, we prepared LN229 glioblastoma transfected with
enhanced green fluorescent protein (EGFP), wild-type EGFR, or EGFRvIII (LN229-WT or -vIII), and examined tumor
growth and microvessel density in the tumors. Additionally, the potential angiogenic factors were identified by
real-time PCR analysis, and the functions in LN229-vIII cells were examined.
Results: LN229-vIII cells showed more aggressive tumor growth and higher vascularity as compared to LN229-WT cells
in vivo, although there was no significant difference in the cell growth rates in vitro. We next investigated the
expression of 60 angiogenesis-related factors to clarify the mechanisms underlying the difference in vascularity
between tumor xenografts of LN229-vIII and LN229-WT. We found that the mRNA and protein expressions of
angiopoietin-like 4 (Angptl4), a secreted protein involved in angiogenesis and metabolism regulation, were significantly
induced by EGFRvIII overexpression, both in vitro and in vivo. Constitutive knockdown of Angptl4 in LN229-vIII using
shRNA significantly decreased the microvessel density in the tumor xenografts and suppressed tumor growth. To clarify
the regulatory mechanisms of Angptl4 by EGFRvIII, we analyzed the signaling pathways and transcription factors by
pharmacological inhibition and RNA interference. U0126, an ERK signal inhibitor dramatically suppressed Angptl4
expression. The transcription factor c-Myc, which is regulated by ERK, was activated in the LN229-vIII cells and
knockdown of c-Myc using siRNA also attenuated Angptl4 expression in the LN229-vIII cells. Furthermore, chromatin
immunoprecipitation (ChIP) assay revealed increased recruitment of c-Myc to the promoter region of Angptl4 in the
LN229-vIII cells.
Conclusions: In summary, we demonstrated that EGFRvIII induces Angptl4 expression through the ERK/c-Myc pathway
and promotes tumor angiogenesis in malignant gliomas.
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Glioblastoma multiforme (GBM), classified as a grade IV
astrocytoma, has an extremely poor prognosis [1]. Long-
term survival of patients with malignant gliomas has
not improved substantially despite the development of
multimodality treatments, including cytoreductive sur-
gery, adjuvant radiation therapy, and cytotoxic chemo-
therapy. In order to develop additional therapeutic
strategies, further understanding of the molecular genet-
ics, biology and immunology of gliomas is desired.
GBMs are distinguished pathologically from lower-grade
anaplastic astrocytomas by the presence of necrosis and
microvascular hyperplasia, a florid form of angiogenesis [2].
Above all, a striking feature of GBMs is the presence of in-
creasing neovascularization [3]. Many studies have demon-
strated that glioma growth is dependent on the generation
of tumor-associated blood vessels [4,5], therefore, use of
antiangiogenic strategies is considered as a promising ap-
proach for the treatment of malignant gliomas.
There has been important progress in the elucidation of
the molecular pathogenesis of malignant gliomas. Two
common and highly specific genetic events associated with
the GBM histology are epidermal growth factor receptor
(EGFR) amplification and loss of the phosphatase and
tensin homologue on chromosome 10 (PTEN) [6,7].
Many studies have revealed that EGFR is functionally
dysregulated in various tumors. Dysregulation of signal
transduction processes affects a variety of downstream
biological processes associated with gene transcription
and protein translation, cell proliferation, migration, adhe-
sion, invasion, and angiogenesis [8]. Abnormalities of
EGFR signaling have also been reported to be observed
frequently in GBMs [9]. EGFR gene amplification or
overexpression is detected in approximately 40% of pa-
tients with these tumors [10,11].
The EGFR variant type III (EGFRvIII), the most com-
mon mutation of EGFR in GBMs, is reported to be
present in 25% to 33% of all cases of GBMs, but only in
those showing EGFR amplification and overexpression
[12]. EGFRvIII overexpression has been shown to induce
tumor growth of GBMs [13] and reported to be corre-
lated with a poor prognosis in clinical settings [14,15].
This EGFR variant is the result of deletion of exons 2 to
7 including the extracellular ligand-binding domain, and
its receptor tyrosine kinase is constitutively active [9].
Because it is not present in normal tissues, it is consid-
ered as a potential target for tumor-specific therapy.
Currently, considerable effort is being made for the de-
velopment of anti-EGFRvIII agents, such as vaccines and
specific antibodies [7,16,17].
EGFR signaling promotes not only cell growth, but
also angiogenesis by induction of proangiogenic factors
such as the vascular endothelial growth factor (VEGF)
and interleukin-8 (IL-8) [18]. Although the NF-kB/IL-8pathway contributes to tumor angiogenesis in EGFRvIII-
overexpressing glioblastomas [19], the EGFRvIII signal-
ing pathways involved in the promotion of angiogenesis
have not yet been clearly elucidated. In this study, we
show the involvement of EGFRvIII in tumor angiogen-
esis in LN229, a GBM cell line, and that the induction of
angiopoietin-like 4 (Angptl4) expression by c-Myc is
involved in EGFRvIII-induced angiogenesis.
Results
Promotion of tumor angiogenesis by EGFRvIII
overexpression
To examine the involvement of EGFRvIII in angiogenesis,
LN229 glioblastoma cells were transduced with retrovirus
vectors encoding enhanced green fluorescent protein
(mock), wild-type EGFR (wtEGFR), or EGFRvIII. The
transfected cells were sorted by EGFP expression from the
viral expression vector using flow cytometry. We observed
that most of the cells expressed EGFP and were altered
morphologically (Additional file 1: Figure S1A), and also
confirmed the expression of wtEGFR and EGFRvIII by RT-
PCR and western blotting (Additional file 1: Figure S1B and
C). The methods of additional figures described in an
additional document (Additional file 2: Supplementary
methods). The cell growth ratio and migration of mock,
wtEGFR-, or EGFRvIII-overexpressing LN229 (LN229-WT
or LN229-vIII) cells were examined in vitro. No significant
change in cell growth rate was observed (Figure 1A) and
cell migration was significantly increased in LN229-vIII
(Additional file 1: Figure S1D). We then examined the ef-
fect of wtEGFR and EGFRvIII on tumor growth in vivo.
Tumor growth was significantly enhanced in the mice bear-
ing tumor xenografts of LN229-vIII as compared with that
in the mice bearing tumor xenografts of LN229-WT
(Figure 1B-D), as previously reported [13,20].
We hypothesized that the microenvironment in the tu-
mors was altered and was involved in the significant tumor
progression, and investigated whether EGFRvIII also pro-
moted tumor angiogenesis in vivo. Frozen sections of the
tumors were prepared and immunostained for CD31, a
representative endothelial cell marker, to examine the
microvessel density in the tumors. The microvessel density
(vessel area/mm2) was significantly augmented in the
EGFRvIII-overexpressing tumors as compared with that in
the mock- and wtEGFR-expressing tumors (Figure 2A and
B). Since the tumor vasculature is a loose structure and
highly permeable [21], we investigated the vascular perme-
ability in the EGFRvIII-overexpressing tumors. Dextran is a
macromolecule that leaks from hyperpermeable blood ves-
sels [22]. Significant increase in the leakage of fluorescent-
labeled dextran from the blood vessels was observed in the
EGFRvIII-overexpressing tumors at 6 h after its adminis-
tration, in contrast to the findings in the mock- and
wtEGFR-expressing tumors (Figure 2C). These data








































































Figure 1 EGFRvIII promotes tumor growth in a mouse xenograft model. (A) The cells (2,000 cells/well) were incubated for 96 hours, and the
cell viability was measured at the indicated times using WST-8. Data shown are the means ± SD (n = 5). (B) Tumor volume in the mice implanted
with mock, wtEGFR, and EGFRvIII-transfected LN229 cells. LN229 cells (3.0 × 106 cells/mouse) were subcutaneously implanted into BALB/c nu/nu
female mice. (C) The tumors were extracted from the mice and weighed at day 26 after tumor implantation. (D) The images of the mice
implanted with tumors (a-c) and of the extracted tumors are shown (d). Data shown are the means ± SEM (n = 10). Significant differences are
shown: * p<0.05, *** p<0.001.
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as well as the microvessel density.
Real-time PCR analysis for identification of EGFRvIII-
related angiogenic factors
Tumor angiogenesis is caused by a disruption of the balance
between proangiogenic and antiangiogenic factors [23]. Since
EGFRvIII increased both the microvessel density and vascu-
lar permeability in the tumor xenografts, it is likely that it
also alters the expression and secretion of angiogenic factors.
To investigate the angiogenic factors regulated by EGFRvIII,
we analyzed the mRNA expressions of these factors by real-
time PCR using a TaqMan Array Gene Signature 96-Well
Plate for Angiogenesis. The analysis showed differences in
the mRNA expressions of ANGPTL4, SERPINB5, KIT,
FOXC2, COL15A1, F2, THBS2 and ITGB3 in the LN229-
vIII cells as compared with that in the mock- and LN229-
WT cells (Additional file 3: Table S1). Among these, theexpression of Angptl4, which has been reported to be a se-
creted protein with proangiogenic activity [24], was markedly
upregulated by EGFRvIII overexpression. Therefore, we fo-
cused on this protein and examined its expression at the
mRNA and protein levels both in vitro and in vivo. Increase
in Angptl4 expression was confirmed by both real-time PCR
and ELISA in vitro (Figure 3A and B). Moreover, increase of
Angptl4 expression in the mice bearing tumor xenografts of
LN229-vIII was observed at both the mRNA and protein
levels (Figure 3C and D). In our experiments, while the
Angptl4 protein was detected in all EGFRvIII-overexpressing
tumors, it was detected in only one of five mock- and two of
five wtEGFR-expressing tumors.
Knockdown of Angptl4 suppressed the growth of
EGFRvIII-overexpressing tumors and tumor angiogenesis
To clarify the role of Angptl4 in the growth and angio-








































IHC staining for CD31
Figure 2 EGFRvIII increases the microvessel density and vascular permeability in tumors. (A) Frozen sections of tumor tissues extracted from
the mice implanted with LN229 cells transfected with mock (a), wtEGFR (b), EGFRvIII (c) were prepared and immunohistochemically stained for CD31, an
endothelial cell marker. Scale bars show 100 μm. (B) Quantitative analysis of the microvessel density in the tumors was performed. At least three fields
were selected from each section. Vessel area/mm2 was measured as the average of the values in four sections/mouse. Data shown are the means ± SEM
(n = 5 mice). Significant differences are shown: *** p<0.001. (C) Permeability of the tumor blood vessels in LN229-tumor bearing mice. The mice were
intravenously injected with TexasRed conjugated dextran (Mw. 70,000, 25 mg/mouse, red, d-f). Subsequently, 6 h after the dextran injection, Alexa647-
conjugated isolectin IB4 (green, a-c), a probe used for specific labeling of endothelial cells, was administered. The mice were sacrificed, and frozen
sections were prepared and observed by fluorescent microscopy. The cell nucleus were labeled with DAPI (blue, g-i). The merged images are shown (j-l).
Scale bars show 50 μm.
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We designed short hairpin RNA (shRNA) to perform
knockdown of Angptl4 with shRNA-expressed retrovirus
vector. After the virus infection and culturing of cells in
G418-containing media, the mRNA expression of Angptl4
was significantly decreased in LN229-vIII cells as mea-
sured by real time PCR analysis (Figure 4A), while
the growth ratio of the cells was not significantly altered
(Figure 4B). The cells expressing shRNA for negative con-
trol (shNC) or Angptl4 (shAngptl4) were subcutaneously
implanted into mice. The tumor volume at day 14 after
implantation of the cells was significantly suppressed byshAngptl4 (Figure 4C). Tumor sections were prepared for
examination of the microvessel density; the microvessel
density was significantly decreased in tumor xenografts of
the Angptl4-knockdown cells (Figure 4D). These results
suggest that Angplt4 promotes, at least in part, tumor
angiogenesis in EGFRvIII-overexpressing tumors.
Transcriptional regulation of Angptl4 by c-Myc
Although it has been reported that Angptl4 transcription
is regulated by the MAPK signal cascade [25], the involve-
ment of Angptl4 transcription in EGFR signaling in glioma











































































































Figure 3 EGFRvIII induces the expression of angiopoietin-like 4 both in vitro and in vivo. Real-time PCR assay of samples obtained from
mock, wtEGFR, and EGFRvIII-transfected LN229 cells (A) and tumors (C) was performed. Total RNA was extracted from the cells or excised tumors
and reverse-transcribed. Real-time PCR was performed based on TaqMan Gene Expression Assays. Beta-actin was used as the endogenous
control. ELISA was performed with cell-conditioned medium (B) and the supernatants of the homogenized tumors (D). Data shown are the
means ± SEM (n=4-6). Significant differences are shown: *** p<0.001. N.D. denotes not detected.
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ways. We therefore investigated the transcriptional regula-
tion of Angptl4 expression by using inhibitors of signaling
pathways including MEK/ERK, JNK, p38, PI3K/Akt, and
JAK which are known to be downstream of the phosphor-
ylation of EGFR [26-29]. Among these, U0126 treatment
dramatically decreased Angptl4 expression in the LN229-
vIII cells (Figure 5A and Additional file 4: Figure S2). In
addition, PD98059 (MEK1 inhibitor) and FR180204 (ATP
competitor of ERK1/2) also decreased Angptl4 mRNA ex-
pression in the cells (Additional file 4: Figure S2). We next
investigated which transcription factors might contribute
to the Angptl4 mRNA expression in LN229-vIII cells.
A transcription factor database search analysis revealed
that the promoter of Angptl4 includes a consensus se-
quence for c-Myc/Max. The activity of the transcriptionfactor c-Myc is regulated by various signaling molecules,
such as ERK [30]. We therefore hypothesized that c-Myc
be activated in LN229-vIII cells through MAPK signaling
to promote Angptl4 transcription. We then investigated
the transcriptional regulation of Angptl4 by c-Myc. A gel-
shift assay showed that Myc/Max was activated in the
LN229-vIII cells and that the activation was suppressed by
treatment with U0126 (Figure 5B and C). To clarify the
role of c-Myc in Angptl4 transcription, an experiment
using RNAi against c-Myc was also performed. Angptl4
mRNA expression in the LN229-vIII cells was significantly
decreased by the knockdown of c-Myc using siRNA
(Figure 5D). Similar results were obtained using another
siRNA for c-Myc (data not shown). In a ChIP assay, bind-
ing of c-Myc to the promoter sequence on Angptl4 was






































































































Figure 4 (See legend on next page.)
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Figure 4 Knockdown of Angptl4 suppresses tumor growth and angiogenesis. (A) The LN229vIII cells were transfected with a retrovirus
vector encoding negative control shRNA (shNC) or Angptl4-targeted shRNA (shAngptl4). The knockdown efficiency of Angptl4 in the LN229vIII
cells was examined by real-time PCR analysis. (B) Cell growth of LN229vIII transfected with shNC or shAngptl4 was measured using WST-8.
(C) Balb/c nu/nu mice were implanted subcutaneously with LN229vIII shNC or shAngptl4 cells, and the tumor volumes were measured on day
21. The excised tumors were photographed. (D) Frozen sections were prepared from the extracted tumors and immunostained for CD31, an
endothelial cell marker (a and b). The nucleus was stained with DAPI (c and d). Scale bars show 100 μm. (E) Quantitative analysis of the
microvessel density in the tumors was performed. At least three fields were selected from each section. Vessel area/mm2 was measured as the
average of the values in four sections/mouse. Data shown are the means ± SEM (n=5 mice). Significant differences are shown: * p<0.05, **
p<0.01.
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Figure 5 Angptl4 gene transcription is mediated by the ERK/c-Myc pathway in LN229-vIII cells. (A) Inhibition of Angptl4 mRNA expression
by treatment with U0126. LN229-vIII cells were treated with U0126 or gefitinib for 24 h. Total RNA was extracted and reverse- transcribed,
followed by real-time PCR. (B) EMSA assay for Myc/MAX using a nuclear extract of LN229 cells transfected with mock, wtEGFR and EGFRvIII. (C)
LN229-vIII cells were treated with U0126 (0.1, 1, 10 μM) for 24 h; thereafter, the nuclear proteins were extracted and used in the EMSA assay.
Complex, the specific DNA-protein (probe/c-Myc) complex. (D) Knockdown of c-Myc in the LN229-vIII cells was accomplished using siRNA.
Angptl4 (black bar) and c-Myc (white bar) mRNA expressions were determined by real-time PCR and normalized to the expression level of β-actin
. Bars show the mean ± SEM (n=4). (E) Formalin-fixed chromatin-protein complexes were sonicated, immunoprecipitated for c-Myc, eluted, and
quantitative PCR for the promoter of Angptl4 was performed. The enrichment was calculated in fold-values by normalization to the negative
control IgG and input control. Bars show the means ± SEM (n=3). Significant differences are shown: ** p<0.01, *** p<0.001.
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c-Myc is activated through the MAPK pathway in the
LN229-vIII cells to directly regulate Angptl4 transcription.
Discussion
Although EGFRvIII has been shown to promote tumor
growth of gliomas through various signaling pathways [9],
the key signal molecules involved in the alteration of the
tumor microenvironment have not yet been fully eluci-
dated. In this study, we investigated whether EGFRvIII
contributes to tumor angiogenesis, and showed dramatic
increases in the microvessel density and vascular perme-
ability in tumor xenografts of LN229-vIII as compared to
LN229-WT in mice, consistent with the results of a previ-
ous study [19]. Considering that hypervascularity is a dis-
tinctive pathological characteristic of malignant gliomas
[31,32], the EGFRvIII expression status may have a great
impact on the clinical picture. Although EGFR is known
to promote angiogenesis by induction of proangiogenic
factors, such as VEGF-A and interleukin 8 [18,33], no dra-
matic induction of angiogenesis by wtEGFR was observed
in our experiments. This difference leads to the specula-
tion that constitutive activation of EGFR may trigger strik-
ing induction of various transcripts, including pro-
angiogenic factors. In order to examine the molecular
mechanisms underlying the induction of angiogenesis by
EGFRvIII, the expressions of 60 angiogenic factors in
LN229 cells were examined by real-time PCR analysis. Al-
though VEGF-A is a representative angiogenic factor and
a possible therapeutic target for glioblastoma [34], VEGF-
A induction by EGFRvIII was observed only to a certain
extent in vivo (data not shown), and not at all in vitro
(Additional file 3: Table S1). Among the 60 angiogenic fac-
tors, we first found that Angptl4 expression was signifi-
cantly induced by EGFRvIII overexpression, and that
Angptl4 acts as a pro-angiogenic factor in tumor xeno-
grafts. Recently, Bonavia, et al. showed that the NF-kB/IL-
8 pathway plays important roles in EGFRvIII-induced
angiogenesis and growth in gliomas [19], however, no sig-
nificant change of the IL-8 expression was observed in our
in vitro experiment (Additional file 3: Table S1). It is likely
that the differences between our results and those of the
previous report are related to differences in the cell lines.
The molecular mechanisms of Angptl4-induced angio-
genesis in malignant gliomas still remain largely unknown.
Angptl4 is expressed in the liver, adipose tissue and pla-
centa, as also in ischemic tissues [35]. It is a member of
the angiopoietin family and is a target of members of the
peroxisome proliferator-activated receptor (PPAR) family,
which are known as metabolic-response transcription fac-
tors [36]. It has been reported that expression of Angptl4
is upregulated under various conditions including hypoxia
and caloric restriction, and transcription factors such as
PPARγ and Smad have been shown to regulate itsexpression [35,37,38]. Increased Angptl4 expression has
been shown in a variety of tumor tissues, such as oral
Kaposi’s sarcoma, esophageal squamous cell carcinoma,
gastric cancer, and colorectal cancer [39-42]. Since a num-
ber of reports have indicated the effects of Angptl4 on
angiogenesis, including endothelial cell proliferation, mi-
gration, differentiation, endothelial cell adhesion, and vas-
cular permeability [43-46], it seems likely that Angptl4
contributes to the increased angiogenesis and vascular
permeability in gliomas formed by EGFRvIII cells. More-
over, it has been demonstrated that Angptl4 disrupts vas-
cular endothelial cell-cell junctions and promotes lung
metastasis of breast cancer cells expressing transforming
growth factor-β [35], while preventing metastasis of mel-
anoma cells [47] and also inhibiting angiogenesis [48].
These diverse and often conflicting results suggest that
Angptl4 exhibit tissue-specific activity and act in accord-
ance with the prevailing cellular environment.
Our results suggest that Angptl4 transcription is regu-
lated, at least partially, by EGFRvIII/ERK/c-Myc-mediated
signaling. EGFR activation induces Ras/MEK/ERK phos-
phorylation, and phosphorylated ERK activates various
transcription factors. It has been shown that MAPK signal-
ing contributes to Angptl4 expression [25]. Myc is known
as an ERK-activated transcription factor [30]. Wild-type
EGFR expression, as compared to mock, increased tumor
growth and Angptl4 expression in vivo, and also activated
ERK phosphorylation in the LN229 cells; however, the de-
gree of activation was not significantly different from that
induced by EGFRvIII expression (data not shown). These
data suggest that, although the MAPK pathway plays an
important role in c-Myc activation, other factors are also
involved in the marked activation of c-Myc and induction
of Angptl4 expression in the LN229-vIII cells. The pro-
moter region of Angptl4 contains the consensus sequence
of c-Myc, ‘CACGTG’. The results of the ChIP assay re-
vealed enhanced binding between c-Myc and the promoter
region of Angptl4 in LN229-vIII cells, suggesting that the
transcriptional regulation of Angptl4 by c-Myc might con-
tribute to the induction of angiogenesis in gliomas. An
MEK inhibitor was also found to markedly inhibit Angptl4
expression in EGFRvIII-overexpressing LN229 cells. In a
previously reported study, combined use of an MEK inhibi-
tor with a PI3K inhibitor effectively suppressed the growth
of gliomas [49]. MEK inhibitors have been examined in
clinical trials for various cancers, and their potential useful-
ness in the treatment of gliomas has been suggested.
Conclusions
In conclusion, we demonstrated in this study that
EGFRvIII induces Angptl4 expression through the ERK/c-
Myc pathway, and that Angptl4 is a possible inducer of
tumor angiogenesis in gliomas expressing EGFRvIII. Since
EGFRvIII strongly induces neovascularization in the
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sible biomarker for predicting the effectiveness of
antiangiogenic therapy, as well as serve as a therapeutic
target, although further studies are needed.
Methods
Cell culture
The human glioblastoma cell lines LN229 (American Tis-
sue Culture Collection) were maintained in Dulbecco’s
minimal essential medium (DMEM, Sigma) supplemented
with streptomycin (100 μg/ml), penicillin (100 units/mL),
and 10% heat-inactivated fetal bovine serum (FBS) at 37°C
under 5% CO2 in a humidified chamber. The cDNA for
wild-type EGFR or EGFRvIII was transfected into LN229
cells by a retrovirus vector, as described previously [17],
and the transfected cells were selected by GFP expression
from the viral expression vector using a cell sorter (BD
Biosciences).
Cell proliferation assay
LN229 cells (1,000 cells/well) were seeded into a 96-well
microtiter plate. After incubation for 24-96 h at 37ºC,
the cell viability was measured with a Cell Counting Kit-
8 (Dojindo, Tokyo, Japan) in accordance with the manu-
facturer’s instructions.
RNA isolation, reverse-transcription PCR, and real-time
PCR
Total RNA was isolated using Isogen (Nippon Gene, Tokyo,
Japan) and the resulting RNA was reverse-transcribed
with the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Tokyo, Japan). Real-time PCR assay
was performed on a StepOnePlus (Applied Biosystems)
using the TaqMan Gene Expression Assays or a TaqMan
Array Gene Signature 96-Well Plate (Angiogenesis, human,
Applied Biosystems). The relative real-time PCR quantifica-
tion was based on a comparative quantitation method.
Western blotting
Western blotting was performed as described previously
[50], with some modifications. The cells were washed with
ice-cold PBS and lysed with M-PER (PIERCE, Tokyo,
Japan) containing protease and phosphatase inhibitors. The
protein concentration was determined using a BCA protein
assay kit (PIERCE). The protein samples were mixed with
SDS-PAGE sample buffer (2% SDS, 10% glycerol, 6% 2-
mercaptoethanol, 50 mM Tris-HCl; pH 6.8), and an equal
amount of proteins in each sample was subjected to SDS-
PAGE. The separated proteins were transferred to a PVDF
membrane (Millipore, Bedford, MA) and blocked with 5%
skim-milk in TBST (0.9% NaCl, 0.1% Tween20, 20 mM
Tris-HCl; pH7.4). The primary antibodies used were anti-
EGFR antibody (BD Pharmingen, NJ) and anti-actin anti-
body (Sigma). Horseradish peroxidase (HRP)-conjugatedantibodies (Cell Signaling Technology, Tokyo, Japan) were
used as the secondary antibodies. The PVDF membrane
was developed with the ECL reagent (GE Healthcare, Buck-
inghamshire, UK).
Tumor xenograft model
LN229 cells were subcutaneously implanted (3.0 × 106
cells/mouse) into the posterior flanks of 4-week old female
BALB/c nu/nu mice. The tumor sizes were monitored as
described previously [51]. Animal studies were carried out
according to the Guideline for Animal Experiments,
drawn up by the Committee for Ethics in Animal Experi-
mentation of the National Cancer Center, which meet the
ethical standards required by law and the guidelines about
experimental animals in Japan.
Microvessel density analysis
After tumor implantation, the mice were sacrificed under
diethyl ether anesthesia, and the tumors were dissected
and weighed. Immunostaining was performed as described
previously [52]. The tumor tissues were embedded and
frozen with dry ice/ethanol. Tumor frozen sections (7 μm)
were prepared and air-dried for at least 1 h. The sections
were fixed with cold acetone, blocked in goat serum for 10
min at room temperature, and then incubated with anti-
mouse CD31 rat monoclonal antibody (BD Pharmingen)
for 18 h at 4°C. The sections were then stained with ABC
Elute kit, or anti-rat IgG-Alexa fluor 555 conjugates (Mo-
lecular Probes, Inc.) for immunohistochemistry and im-
munofluorescent staining, respectively. After mounting
the sections, the images were examined and scanned with
Biozero (Keyence, Tokyo, Japan) at 20 × magnification.
For quantitative analysis, the vascular area/mm2 in the tu-
mors was quantified by counting the CD31-positive area
in independent hotspots of at least four different micro-
scopic fields in each of five mice/group, using the ImageJ
software. The four fields were averaged in each tumor and
the averages for each animal used to express the final
count ± SEM.
Vascular permeability
The in vivo vascular permeability assay was performed as
described previously with some modifications [53]. The
tumor-implanted mice were intravenously injected with
TexasRed conjugated dextran (50 mg/kg/mouse, Mw
70,000, Molecular probes, Inc). At 6 h after the injection,
Alexa647-conjugated Isolectin IB4 (Molecular probes, Inc)
was injected for fluorescent staining of the blood vessels.
After 10 minutes, perfusion fixation was performed under
ether anesthesia and the tumors were extracted from the
mice. The extracted tumors were frozen and sectioned as
described above. The sections were fixed with 4% parafor-
maldehyde, mounted, and observed by fluorescent micros-
copy as described above.
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LN229 cells were seeded (3.0 × 105 cells) in a 35-mm dish
and incubated overnight. The medium was refreshed and
the culture dish was incubated for a further 48 h at 37°C.
The culture medium was collected and centrifuged at
1,000 g for 10 min. The supernatant was recovered and
ELISA for Angptl4 was performed using the Human
Angiopoietin-like 4 DuoSet ELISA kit (R&D Systems,
Minneapolis, MN) with a sensitivity of 1.25 ng⁄mL, an
intra-assay coefficient of variation of 0.6–7.6%, and an
inter-assay coefficient of variation of 8.5–11.2%. The assay
was performed in accordance with the manufacturer’s in-
structions. The remaining cells on the dishes were lysed
and the amount of protein was measured by a BCA pro-
tein assay. Tumor tissues extracted from the mice were
homogenized in PBS (–) and centrifuged at 10,000 × g for
10 min at 4°C. The supernatant was collected and ELISA
was performed as described above. Duplicate measure-
ments were performed in a single experiment.
Electrophoretic mobility shift assay (EMSA)
Nuclear fractions were extracted from the LN229 cells
using a Nuclear Extraction kit (Panomics, Redwood City,
CA). The EMSA binding assay was carried out using a
Panomics EMSA “gel shift” kit in accordance with the
manufacturer’s instructions. Assays were conducted using
a biotin-labeled double-stranded oligonucleotide having a
consensus recognition sequence for Myc/Max purchased
from Panomics. Protein-DNA complexes were separated
using nondenaturing PAGE. The oligonucleotides were
secondarily probed with HRP-conjugated streptavidin and
developed with the component solution by LAS4000.
RNAi experiment
The RNAi experiment was performed with the
Lipofectamine RNAiMAX reagent (Invitrogen, Tokyo,
Japan) in accordance with the manufacturer’s instructions.
The sequences of siRNA for c-Myc were 5′-AGA CCU
UCA UCA AAA ACA UTT-3′ (sense) and 5′-AUG UUU
UUG AUG AAG GUC UCG-3′ (antisense), which were
designed by Ambion, and the non-silencing control siRNA
was purchased from Invitrogen. After incubation with the
siRNA for 48 h at 37°C, the mRNA expressions of c-Myc
and Angptl4 were quantitatively determined by real-time
PCR. Short hairpin RNA targeting the Angptl4-including
entry vector was designed and prepared by Invitrogen. The
shRNA was subcloned to a retrovirus vector and used in
the experiments as described in a previous study [17].
ChIP assay
The ChIP assay was performed using the ChIP IT Express
kit (Active Motif, Carlsbad, CA), in accordance with the
manufacturer’s instructions. LN229 cells were fixed with
1% formaldehyde for 10 min. The cells were then washed,lysed, and sonicated to reduce DNA lengths to the range
of 200 to 1500 bp. The chromatin/DNA complexes were
incubated with antibodies to c-Myc (Santa Cruz Biotech-
nology, CA) or IgG (Cell Signaling Technology) overnight
at 4°C. The immune complexes were precipitated, eluted,
reverse-crosslinked, and treated with proteinase K. After
extraction of the DNA fragments, real-time PCR analysis
was performed using Power SYBR green PCR master
mixes (Applied Biosystems). The primer for the promoter
of Angptl4 was purchased from BioScience (Fredrick,
MD), and was as follows: forward, 5′-TAC TAG CGG
TTT TAC GGG CG-3′; reverse, 5′-TCG AAC AGG AGG
AGC AGA GAG CGA-3′. The predicted PCR product in-
cluded a c-Myc binding sequence. Relative enrichment was
comparatively calculated using IgG negative control as de-
scribed in eBioScience instructions.
Statistical analysis
Significant differences were analyzed by an unpaired
Student’s t-test or analysis of variance (ANOVA) with
Tukey’s post-hoc test using the GraphPad Prism software
(Version 5.0). p < 0.05 was considered to indicate statisti-
cally significant difference.Additional files
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